

**Alcohol, and HIV-AIDS Comorbidities,
Coinfections, and Complications Research:**
Intervention and Cross-Cutting Foundational Research

Kendall Bryant, Ph.D.

Director HIV/AIDS and Alcohol Research, NIAAA/NIH


Purpose: *Ending the Epidemic*

This future Funding Opportunity Announcement will continue NIAAA-supported programs that will advance operations or implementation research in the context of alcohol and HIV/AIDS (RFA AA-16-001)

- 1) to continue to develop a broader systems approach for **monitoring** complex HIV and alcohol-related morbidity and mortality;
- 2) to **intervene** to reduce the impact of alcohol and HIV disease progression and transmission;

NIH Priorities for HIV and HIV-Related Research

HIV/AIDS research at the NIH is a continuum from basic science through implementation research. The NIH supports this continuum through the institutes and centers in collaboration with other government agencies and nongovernmental organizations.



Reduce Incidence

- Vaccines
- PrEP, U=U
- Microbicides & MPTs
- HIV Testing
- Treatment as Prevention
- Monoclonal Antibodies

Research Toward A Cure

- ART-free Viral Remission
- Viral Eradication
- Viral Latency & Sanctuaries
- Cure Ethics & Acceptability

Cross-Cutting Areas

- Virology & Immunology
- Behavioral & Social Sciences
- Epidemiology
- Health Disparities
- Information Dissemination
- Implementation Science
- Infrastructure, Capacity Building


Next-Gen HIV Therapies

- Less Toxic, Longer Lasting ART
- Novel HIV Targets & Inhibitors
- Novel Immune-Based Therapies
- Adherence & Retention-Care

Comorbidities, Coinfections, & Complications

- Coinfections
- Neurologic Complications
- Malignancies
- Cardiovascular Complications
- Mental Illness/Substance Use
- Metabolic Disorders
- Across the Lifespan

Comorbidities, Coinfections, Complications



Goals: Interventions and Implementation Research

- Develop interventions that combine behavioral and biological strategies
- Discover innovative approaches to measure and treat HIV and alcohol misuse in diverse populations
- Develop strategies to prevent HIV and common alcohol-associated coinfections.
- Support and advance novel research to address and mitigate underlying alcohol and HIV-associated medical and social inequalities


Goals: Foundational and Preclinical Research

- Pursue innovative research methods and the use of new and improved technologies
- Use emerging new methodologies focused on analysis and representation of large/complex datasets
- Advance the understanding of how the severity of alcohol use (including Alcohol Use Disorders) impacts clinical outcomes for PLWH
- Examine the additive or synergistic impact for specific comorbidities in determining clinical outcomes for PLWH who have sustained organ and tissue damage

Outcomes include monitoring progress to improve the health of People Living with HIV (PLWH)

- improving **linkage to care** and retention in HIV and alcohol care
- accelerating **reductions in alcohol use** resulting in **increased viral suppression**
- identifying mitigating **social determinants of poor outcomes** such as homelessness
- reducing **frailty** and subsequent mortality related to aging
- reducing the **incidence** of new Infections and
- reducing HIV and alcohol disparities in key populations of men and women and in the *Southern US and other high-incidence locations.*

Ending the HIV Epidemic in the U.S.



Focus resources in:

- 48 highest burden counties
- Washington, D.C.
- San Juan, Puerto Rico
- 7 states with a substantial rural HIV burden.

Ending
the
HIV
Epidemic

Contact Information

Kendall Bryant, Ph.D
Phone: 301-402-0332
Email: kendall.bryant@nih.gov

| Name | Division | Phone/Email |
|------------------------|--|--|
| John Matochik, Ph.D. | Division of Neuroscience and Behavior | Phone: 301-451-7319 Email: jmatochi@mail.nih.gov |
| Li Lin, PhD | Division of Metabolism and Health Effects | Phone: 301-443-1275 Email: linli@mail.nih.gov |
| Joe Wang, PhD | Division of Metabolism and Health Effects | Phone: 301-451-0747 Email: wangh4@mail.nih.gov |
| Deidra Roach, MD | Division of Treatment and Recovery Research | Phone: 301-443-5820 Email: droach@mail.nih.gov |
| Tatiana Balachova, PhD | Division of Epidemiology and Prevention Research | Phone: 301-443-5726 Email: tatiana.balachova@nih.gov |
| Robert C. Freeman, PhD | Division of Epidemiology and Prevention Research | Phone: 301-443-8820 Email: rfreeman@mail.nih.gov |
| Daniel Falk, PhD | Division of Medications Development | Phone: 301-443-0788 Email: falkde@mail.nih.gov |